FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289596362> ?p ?o ?g. }

• W4289596362 endingPage "122080" @default.
• W4289596362 startingPage "122080" @default.
• W4289596362 abstract "Despite the effectiveness and high tolerability of vilazodone (VLZ) as an antidepressant, its use is still limited due to its poor solubility and food dependent absorption. This study aims to load VLZ-phospholipid complex into self-assembled micelles forming VLZ-PL mixed micelles (VLZ-PL-MM), that can enhance VLZ solubility, improve its bioavailability and reduce the pharmacokinetic variability between the fed and fasting conditions. The effect of surfactant type and concentration was assessed using four different non-ionic surfactants (Brij 58, Tween 80, Labrasol and Pluronic F127) in four different weight ratios between the drug-complex and surfactant (1:0.5, 1:1, 1:2 and 1:3 w/w). Two VLZ-PL-MM formulae prepared using Brij 58 and Labrasol in 1:3 w/w ratio were selected as optimised ones since they have the highest encapsulation efficiency (100.83 and 93.87%, respectively), a particle size below 250 nm (206.73 and 221.33 nm, respectively) and negative zeta potential values (-29.63, -17.20 mV, respectively). Lyophilisation of these formulations using 3% sucrose was successful with no statistical changes in particle size and zeta potential upon rehydration. Both formulations elicited faster and higher in-vitro drug release profiles compared to the pure drug and the marketed tablet. In addition, both selected formulae improved ex-vivo permeation across rabbit intestinal membrane compared to the pure drug and the marketed tablet, with marked superiority of the one prepared using Brij 58. The results of the in-vivo study in male albino rabbits revealed similar AUC0-24 values after the oral administration of the best achieved VLZ-PL-MM system under fed and fasted conditions (769.89 and 741.55 ng.h mL-1, respectively). On the other hand, the marketed product showed significantly lower values of the AUC0-24 relative to the VLZ-PL-MM system and there was a marked enhancement of absorption of drug from the marketed product in presence of food (244.24 and 174.96 ng.h mL-1 under fed and fasted conditions, respectively). In addition, VLZ concentrations in the brain after 24 h obtained from the selected VLZ-PL-MM were significantly higher than those obtained from marketed tablet under fed and fasted conditions. Thus, the phospholipid mixed micelles formulation enhances the oral bioavailability of the poorly soluble drug and reduces the pharmacokinetic variability between fasting and fed conditions." @default.
• W4289596362 created "2022-08-03" @default.
• W4289596362 creator A5015094210 @default.
• W4289596362 creator A5024567840 @default.
• W4289596362 creator A5055452355 @default.
• W4289596362 creator A5062807614 @default.
• W4289596362 creator A5069328902 @default.
• W4289596362 date "2022-09-01" @default.
• W4289596362 modified "2023-09-23" @default.
• W4289596362 title "Vilazodone-phospholipid mixed micelles for enhancing oral bioavailability and reducing pharmacokinetic variability between fed and fasted states" @default.
• W4289596362 cites W1972116828 @default.
• W4289596362 cites W1975970944 @default.
• W4289596362 cites W1979276019 @default.
• W4289596362 cites W1989914947 @default.
• W4289596362 cites W1990376788 @default.
• W4289596362 cites W2016382049 @default.
• W4289596362 cites W2039685150 @default.
• W4289596362 cites W2045932974 @default.
• W4289596362 cites W2046842688 @default.
• W4289596362 cites W2048389616 @default.
• W4289596362 cites W2049836683 @default.
• W4289596362 cites W2059291872 @default.
• W4289596362 cites W2066793708 @default.
• W4289596362 cites W2136288863 @default.
• W4289596362 cites W2184999295 @default.
• W4289596362 cites W2290466312 @default.
• W4289596362 cites W2309504753 @default.
• W4289596362 cites W2322790968 @default.
• W4289596362 cites W2465428371 @default.
• W4289596362 cites W2561715838 @default.
• W4289596362 cites W2579811554 @default.
• W4289596362 cites W2582716970 @default.
• W4289596362 cites W2597556959 @default.
• W4289596362 cites W2609892620 @default.
• W4289596362 cites W2783307759 @default.
• W4289596362 cites W2793276275 @default.
• W4289596362 cites W2796711809 @default.
• W4289596362 cites W2801839660 @default.
• W4289596362 cites W2804846127 @default.
• W4289596362 cites W2805030945 @default.
• W4289596362 cites W2887799451 @default.
• W4289596362 cites W2888140909 @default.
• W4289596362 cites W2890372017 @default.
• W4289596362 cites W2923435777 @default.
• W4289596362 cites W2963615747 @default.
• W4289596362 cites W3033623110 @default.
• W4289596362 cites W3043350415 @default.
• W4289596362 cites W3134531697 @default.
• W4289596362 cites W3138845742 @default.
• W4289596362 cites W3145528444 @default.
• W4289596362 cites W3169808694 @default.
• W4289596362 cites W3210477005 @default.
• W4289596362 cites W363277683 @default.
• W4289596362 cites W4247645630 @default.
• W4289596362 cites W4280548201 @default.
• W4289596362 cites W584914605 @default.
• W4289596362 doi "https://doi.org/10.1016/j.ijpharm.2022.122080" @default.
• W4289596362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35932929" @default.
• W4289596362 hasPublicationYear "2022" @default.
• W4289596362 type Work @default.
• W4289596362 citedByCount "2" @default.
• W4289596362 countsByYear W42895963622023 @default.
• W4289596362 crossrefType "journal-article" @default.
• W4289596362 hasAuthorship W4289596362A5015094210 @default.
• W4289596362 hasAuthorship W4289596362A5024567840 @default.
• W4289596362 hasAuthorship W4289596362A5055452355 @default.
• W4289596362 hasAuthorship W4289596362A5062807614 @default.
• W4289596362 hasAuthorship W4289596362A5069328902 @default.
• W4289596362 hasConcept C11268172 @default.
• W4289596362 hasConcept C112705442 @default.
• W4289596362 hasConcept C147789679 @default.
• W4289596362 hasConcept C150903083 @default.
• W4289596362 hasConcept C155574463 @default.
• W4289596362 hasConcept C155672457 @default.
• W4289596362 hasConcept C171250308 @default.
• W4289596362 hasConcept C178790620 @default.
• W4289596362 hasConcept C181389837 @default.
• W4289596362 hasConcept C184651966 @default.
• W4289596362 hasConcept C185592680 @default.
• W4289596362 hasConcept C187530423 @default.
• W4289596362 hasConcept C192562407 @default.
• W4289596362 hasConcept C201399114 @default.
• W4289596362 hasConcept C207001950 @default.
• W4289596362 hasConcept C2778918659 @default.
• W4289596362 hasConcept C41625074 @default.
• W4289596362 hasConcept C43617362 @default.
• W4289596362 hasConcept C50670333 @default.
• W4289596362 hasConcept C55493867 @default.
• W4289596362 hasConcept C58226133 @default.
• W4289596362 hasConcept C71240020 @default.
• W4289596362 hasConcept C71924100 @default.
• W4289596362 hasConcept C86181022 @default.
• W4289596362 hasConcept C86803240 @default.
• W4289596362 hasConcept C98274493 @default.
• W4289596362 hasConceptScore W4289596362C11268172 @default.
• W4289596362 hasConceptScore W4289596362C112705442 @default.
• W4289596362 hasConceptScore W4289596362C147789679 @default.
• W4289596362 hasConceptScore W4289596362C150903083 @default.

• next